PEX13 and PEX14 are two core components of the so-called peroxisomal docking/translocation module, the transmembrane hydrophilic channel through which newly synthesized peroxisomal proteins are translocated into the organelle matrix. The two proteins interact with each other and with PEX5, the peroxisomal matrix protein shuttling receptor, through relatively well characterized domains. However, the topologies of these membrane proteins are still poorly defined. Here, we subjected proteoliposomes containing PEX13 or PEX14 and purified rat liver peroxisomes to protease-protection assays and analyzed the protected protein fragments by mass spectrometry, Edman degradation and western blotting using antibodies directed to specific domains of the proteins. Our results indicate that PEX14 is a bona fide intrinsic membrane protein with a N in -C out topology, and that PEX13 adopts a N out -C in topology, thus exposing its carboxyterminal Src homology 3 [SH3] domain into the organelle matrix. These results reconcile several enigmatic findings previously reported on PEX13 and PEX14 and provide new insights into the organization of the peroxisomal protein import machinery. 
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Introduction
Peroxisomal matrix proteins are synthesized on cytosolic ribosomes and rapidly transported to the organelle [1] . Their correct sorting depends on peroxisomal targeting signals (PTS), small peptide sequences embedded in their primary structures. There are two types of targeting signals, the so-called PTS1 and PTS2, respectively. The most common of these, the PTS1, is a carboxy-terminal peptide frequently ending with the sequence S-K-L. The PTS2 is a degenerated nonapeptide present at the N-termini of a few matrix proteins [2, 3] .
The machinery that transports these proteins to the peroxisome matrix comprises many different components [4] [5] [6] [7] . Most are exclusively dedicated to this task -these belong to the so-called peroxin family [8] . Others, such as ubiquitin, are also involved in other biological functions. From a functional/structural perspective, these components can be grouped into four sets:
(a) the shuttling receptors/transporters, which in most organisms, including mammals, are PEX5, for PTS1 proteins, and the PEX5-PEX7 complex for PTS2 proteins [9] [10] [11] [12] ; (b) the docking/translocation module (DTM), a peroxisomal transmembrane protein complex comprising the core components PEX13 and PEX14 and the RING finger proteins PEX2, PEX10 and PEX12 [13, 14] ; (c) the receptor export module (REM), a complex comprising PEX1 and PEX6, two ATPases belonging to the AAA (ATPases associated with diverse cellular activities) family, and a poorly conserved peroxisomal membrane anchor protein which receives different names in different organisms (i.e., PEX26 in mammals, PEX15 in some yeasts and fungi, and APEM9 in plants) [15] [16] [17] ; and lastly, (d) a group of proteins involved in ubiquitination/deubiquitination events, namely the ubiquitin-activating enzyme and ubiquitin as well as ubiquitinconjugating enzymes (e.g., E2D1/2/3 in mammals or the PEX4.PEX22 complex in yeasts and plants) and a deubiquitinase [18] [19] [20] [21] [22] .
The way this machinery works resembles the mechanism of a syringe [5] . The receptors (the 'syringe plungers') bind their cargoes in the cytosol and insert themselves into the DTM (the 'syringe barrel') thus pushing their cargoes into the peroxisome matrix [23] [24] [25] . Insertion of the 'plunger' into the 'barrel' is a regulated event -only cargo-loaded receptors display the capacity to enter the DTMbut, notably, it requires no ATP hydrolysis or a membrane potential [23, 26, 27] . Apparently, the driving force for protein translocation across the peroxisomal membrane resides solely on protein-protein interactions [26] . The need for chemical energy input comes only at the next steps, when the 'syringe' is disassembled. First, DTM-embedded PEX5 is monoubiquitinated at a conserved cysteine residue [22, 28] . Then, the REM extracts monoubiquitinated PEX5 into the cytosol in an ATP hydrolysis-dependent manner, a step that also results in the release of DTM-embedded PEX7 [26, [29] [30] [31] [32] . Finally, monoubiquitinated PEX5 is rapidly deubiquitinated in the cytosol [18, 20, 33] .
Many crucial aspects of this protein sorting pathway remain unknown. An important one regards the DTM, the transmembrane protein complex through which newly synthesized PTS1 and PTS2 proteins are translocated into the peroxisome matrix. This complex has the remarkable capacity of accepting already folded proteins as substrates (reviewed in [34, 35] ), but our knowledge on its architecture is close to none. For instance, despite an abundance of data on protein-protein interactions involving DTM-components and their domains [13, 14, [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] , the different membrane topology models presently available for some of its components make any attempt to draw a coherent picture of this complex a difficult task [47, 48, [50] [51] [52] [53] [54] [55] [56] [57] .
In this work, we focused on PEX13 and PEX14, two of the best characterized DTM components. The two proteins interact with each other and with PEX5 in a variety of organisms, and several findings suggest that they can form homo-oligomers, a property that might be used to assemble pore-like structures at the organelle membrane [13, 14, [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] . Furthermore, semiquantitative western blot analyses of purified organelles [14] and a variety of proteomic studies (compiled in PaxDb, a database of protein abundance; [58] ) suggest that PEX14 is stoichiometrically more abundant than any other subunit of the DTM. This property, together with the fact that PEX14 possesses a phylogenetically conserved putative transmembrane domain (see Fig. 1 ), might suggest that PEX14 is a major structural building-block of the peroxisomal protein translocon. However, the experimental data on the membrane topology of this protein are scarce and frequently contradictory, even in similar organisms. For example, PEX14 has been described as a peripherally associated component of the peroxisomal membrane in some organisms [50, 54] and as a transmembrane protein in others [39, 47, 52, 56, 59] , but even in the latter situation there is no consensus regarding its membrane topology [44, 48] . For PEX13 the membrane topology data are also scarce, but it is generally assumed that the protein has two transmembrane domains (despite the fact that at least a third one is predicted by some algorithms; see Fig. 1 ) and exposes both the N and C terminus into the cytosol [47, 53, 57, 60, 61] . The problem with this model is that it places the C-terminal SH3 domain exposed to the cytosol, a topology difficult to conciliate with the proposed role of this PEX13 domain in cargo-release from PEX5 [45, 57, 62] . Furthermore, since the SH3 domain of PEX13 interacts with the N-terminal fourth of PEX14 (see Fig. 1 ) [41, 47, 63] , such a topology seemingly collides with models that place that region of PEX14 inside the peroxisome.
Here, we reconstituted recombinant rat PEX13 and PEX14 into liposomes and used these proteoliposomes in protease-protection assays. Analyses of the protease-protected fragments using several approaches together with experiments performed using purified rat liver peroxisomes provide new insights on the topologies of these proteins.
Results
Liposome reconstitution experiments reveal that recombinant PEX14 can acquire a transmembrane topology in an autonomous manner
The interaction of PEX14 with the peroxisomal membrane as well as the topology that this protein acquires in this membrane system has been characterized in several organisms using a variety of techniques. However, as stated above, the data presently available result in inconsistent topology models. We reasoned that reconstituting this protein into liposomes might provide new insights into this issue.
For this, we first expressed a fusion protein comprising (from the N to the C terminus) a histidine-tag, a tobacco etch virus (TEV)-cleavage site, and rat PEX14 (H 6 TEVPEX14) in Escherichia coli (see Fig. 2A ), purified the n-dodecyl-b-D-maltopyranoside (DDM)-solubilized protein by immobilized metal affinity chromatography (IMAC), removed or not the histidine-tag with the TEV protease, and reconstituted Putative transmembrane domains (TMDs; light blue cylinders) were predicted with PRALINE TM [83] and PHOBIUS [84] using an alignment of twenty protein sequences representative of eukaryotic evolution. The pentapeptide motifs of PEX5 [43] are represented in orange. Black lines indicate the epitopes recognized by some of the antibodies used in this work. The interactions between PEX13, PEX14 and PEX5 are indicated as red (yeast) or blue (mammals) arrows. The SH3 domain of yeast PEX13 interacts with a PXXP motif (residues 87-90) located between the NTD and TMD of PEX14 [61, 85] . In mammals, the SH3 domain of PEX13 interacts with the NTD of PEX14 [41, 63] . The region comprising amino acid residues 236-246 of yeast PEX13, which corresponds to a region in the mammalian peroxin located between TMD2 and TMD3, interacts with an undefined region (marked with '?') of PEX14 [47] . The SH3 of PEX13 also interacts with the N-terminal half of PEX5 in yeast [36, 37, 85] . A similar interaction involving residues 219-403 of human PEX13 (which includes the SH3 domain) and the N-terminal half of PEX5 has been described [38] . Residues 1-135 of mammalian PEX13 were also reported to interact with pentapeptides motifs 2-4 of PEX5 [45] . The NTD of PEX14 interacts with pentapeptide motifs present in the N-terminal half of PEX5 both in mammals and yeast/fungi [43, 45, 49, 71, 86] . A C-terminal domain of yeast PEX14 (residues 235-341) has been shown to interact with PEX5 [49, 71] , an interaction involving the second pentapeptide motif of PEX5 [49] (Reviewed in [51, 57, 70] ). ) in the presence or absence of TX-100, and analyzed by SDS/PAGE/western blot. PEX14 was detected with antibodies against the full-length (FL) protein. Equivalent amounts of recombinant proteins (Lanes I; 130 ng) and the corresponding reconstituted proteins were loaded onto the gels. (C) As in B, but using PEX14 that was subjected to the reconstitution protocol in the absence of lipids. (D) As in B, but using antibodies directed to the full-length protein, the C-terminal residues 327-377 of human PEX14, and the N-terminal histidine-tag. (E) PEX14 proteoliposomes were treated with PK (400 lgÁmL À1 ) or trypsin (Try, 400 lgÁmL
À1
) and analyzed by SDS/PAGE/ western blot using an antibody against the full-length protein. The~46-kDa PEX14 fragment obtained after trypsin digestion is recognized by the anti-PEX14 (327-377) antibody (data not shown). Identical results were obtained with H 6 TEVPEX14; in this case, the two fragments with~20 and~30 kDa are recognized by the anti-His antibody (data not shown), suggesting that the 30-kDa fragment is a partial proteolysis product. (F) Proteoliposomes, PK-treated proteoliposomes, and PK alone were subjected to SDS/PAGE, blotted onto a Sequi-blot PVDF membrane and stained with Coomassie Brilliant Blue. PK-resistant fragments of PEX14 ( , 40 kDa and~20 kDa) and protein bands derived from PK itself (*) are indicated. (G) PEX14 proteoliposomes (Lipos) and purified rat liver peroxisomes (Peroxis) were treated or not with PK (400 lgÁmL À1 ) in the presence or absence of TX-100 and analyzed as in B. PEX14 was detected with antibodies against the full-length protein. Note that the faint 30-kDa band in PK-treated peroxisomes results from incomplete digestion of PEX14 by PK (see [44] for details). Numbers to the left indicate the molecular masses of protein standards in kDa.
the proteins into liposomes using published procedures [64] [65] [66] .
We then used these liposomes in protease-protection assays. Fig. 2B (left panel) shows the results obtained with TEV-cleaved PEX14 (note: although this protein contains two extra amino acid residues before the initial methionine of PEX14, we hereafter refer to it as PEX14, for simplicity). After treatment of the proteoliposomes with a large amount of proteinase K (PK; see Materials and methods) two protease-protected PEX14 fragments were detected on western blots using an antibody made against full-length PEX14, one of which migrates with an apparent mass of approximately 20 kDa and the other of around 40 kDa. The relative amounts of these two fragments varied somewhat between different experiments. Although the reason for this phenomenon was not addressed in our work, it is apparent that there are two PEX14 populations in these liposomes. Importantly, no PEX14 fragments were detected in these liposomes when the protease treatment was made in the presence of TX-100 ( Fig. 2B , left panel), a mild detergent that solubilizes membrane lipids. Similarly, no PEX14 fragments were detected with a PEX14 protein that had been subjected to the reconstitution protocol in the absence of lipids (Fig. 2C) , although in this case a small amount of full-length PEX14, possibly representing aggregated protein, was observed.
Due to the fact that we presently lack antibodies specifically directed to the N terminus of PEX14, proteoliposomes containing intact recombinant H 6 TEV-PEX14 were also prepared. In this way, commercially available anti-histidine-tag antibodies (anti-His) could be used to determine whether any of the protease-protected fragments retains the N terminus of PEX14. The results obtained with these proteoliposomes (see Fig. 2B , right panel) are very similar to those observed for the TEV-cleaved protein. The major difference regards the smaller PEX14 fragment, which now displays a slightly larger apparent mass of ca. 23 kDa, suggesting that it still contains the histidine-tag, as indeed shown below. The other difference regards the presence of a residual amount of intact H 6 TEVPEX14 in the protease-treated liposomes sample. We note that this species was detected only occasionally and also with other proteins, and probably represents nonreconstituted aggregated protein and/or protein encapsulated in liposomes.
To define the PEX14 fragments obtained in these protease-protection assays, we first probed western blots of PEX14/H 6 TEVPEX14 proteoliposomes digested or not with PK with the anti-His antibody and with an antibody directed to the carboxy-terminal 51 residues of human PEX14 [anti-PEX14 (327-377)]. The results of these experiments (see Fig. 2D ) show that the anti-PEX14 (327-377) antibody recognizes the 40-kDa PK-resistant fragment but not the smaller 20-kDa PEX14 fragment, whereas the anti-His antibody detects the 23-kDa fragment in the H 6 TEVPEX14 proteoliposomes but not the 40-kDa fragment. Thus, the 20-23 kDa fragments contain the N terminus of PEX14 whereas the 40-kDa species corresponds to a C-terminal fragment of PEX14. It should be emphasized that the two PEX14 fragments detected in these experiments are generated by PK and not the result of encapsulation of the truncated PEX14 species that are already present in the non-reconstituted purified protein (see Fig. 2A ). In the latter situation, treatment of PEX14 proteoliposomes with a different protease (e.g., trypsin) should result in an identical band pattern, which is not the case, as shown in Fig. 2E .
Additional data confirming the identities of the two PEX14 fragments described above were obtained by MS analyses. As shown in Tables 1 and 2 , several peptides derived from the region encompassing residues 1-90 of PEX14 were detected in the analyses of the 20-kDa fragment, whereas 32 of the 33 peptides identified in the analyses of the 40-kDa PEX14 fragment map to the residues 129-376 of PEX14. We have also subjected the 40-kDa fragment of PEX14 (see Fig. 2F ) to Edman degradation. The sequence obtained, SPGSS, corresponds to residues 100-104 of PEX14, a site very close to the putative TMD of PEX14 (see Fig. 1 ). Together, these findings suggest that PEX14 acquires two different membrane topologies in these liposomes: one with a N in -C out topology (this one yields the 20-kDa fragment upon PK digestion) and the other with a N out -C in topology (yielding the 40-kDa species upon PK treatment).
Lastly, we performed a side-by-side comparison of PK-treated liposomes and purified rat liver peroxisomes by SDS/PAGE/western blotting. The results revealed that the 20-kDa PEX14 fragment detected in the liposome sample migrates only slightly above the fragment detected with the endogenous protein ( Fig. 2G ), which as shown before corresponds approximately to amino acid residues 1-130 of PEX14 [44] . The fact that the TEV-cleaved recombinant protein possesses two additional amino acid residues before the initial methionine of PEX14 together with the possibility that endogenous rat PEX14 may lack its initial methionine (this is the case for human PEX14 which is N-acetylated at its second residue [67] ), probably explains this difference.
In conclusion, these experiments show that recombinant PEX14 can adopt a transmembrane topology in an autonomous manner. Thus, there is no need to assume that peroxisomal PEX14 is a peripheral membrane protein that acquires a transmembrane topology only when interacting with other components of the protein import machinery (see also Discussion).
Redefining the membrane topology of PEX13
In contrast to recombinant H 6 TEVPEX14, which can be obtained in large amounts, recombinant H 6 TEV-PEX13 is very poorly expressed in E. coli (see Fig. 3A ). Nevertheless, we were able to detect PK-resistant material in proteoliposomes containing H 6 TEVPEX13 or the TEV-cleaved protein (PEX13) by western blot analyses. Indeed, as shown in Fig. 3B , both reconstituted proteins are cleaved by PK into a 28-kDa fragment which is recognized by an antibody directed to amino acid residues 219-403 of human PEX13. As expected, no PK-resistant fragment is observed when the protease treatment of proteoliposomes is performed in the presence of TX-100 (see Fig. 3B ) or when using PEX13 that had been subjected to the reconstitution protocol in the absence of lipids (Fig. 3C) . Importantly, the 28-kDa fragment co-migrates exactly with that obtained after PK treatment of rat PEX13 in purified peroxisomes (Fig. 3D) , strongly indicating that at least a fraction of the recombinant protein acquired a correct membrane topology. We note that this 28-kDa fragment was previously detected in PK-treated rat liver peroxisomes using an antibody made against the full- length protein [68] . Based on the accepted topology model for PEX13 (see Introduction), that work assumed that such a fragment represented an intraperoxisomal loop domain of PEX13, that is, a fragment starting before the TMD1 of PEX13 and ending after its TMD3 (the two consensual TMDs; see Fig. 1 ), an assumption that is wrong, as shown below. Aiming at better defining the membrane topology of reconstituted PEX13, we tried to detect PEX13 species in these proteoliposomes displaying an inverted membrane topology. For this, we first analyzed PK-treated proteoliposomes containing H 6 TEVPEX13 by western blotting using the anti-His antibody (see Fig. 4A ). However, no convincing data for the existence of a protease-resistant fragment was obtained, suggesting that the majority of recombinant PEX13 in these proteoliposomes acquires a single membrane topology. Nevertheless, considering that the anti-His antibody used in these experiments is not particularly sensitive, we probed western blots containing PEX13 liposomes with a commercially available antibody directed to the last 62 amino acid residues of human PEX13 [anti-PEX13 (342-403)]. As shown in Fig. 4A , this antibody did detect a robust PEX13 fragment in PK-treated liposomes. However, to our surprise, this fragment comigrates exactly with the 28-kDa fragment detected with the anti-PEX13 (219-403) antibody. More importantly, the same 28-kDa PEX13 fragment was detected with both the anti-PEX13 (219-403) and anti-PEX13 (342-403) antibodies in PK-treated purified rat liver peroxisomes (see Fig. 4B ), indicating that the 28-kDa fragment corresponds to a C-terminal domain of PEX13 and not to the putative intraperoxisomal loop domain of PEX13 referred to above. In face of these results, we questioned the identity of the commercial anti-PEX13 (342-403) antibody. However, epitopemapping experiments revealed that this antibody indeed recognizes a fragment comprising residues 342-403 of PEX13 but not one containing residues 1-341 of the protein, in contrast to the anti-PEX13 (219-403) antibody which recognizes both PEX13 fragments (see Fig. 4C ). Thus, the carboxy-terminal domain of PEX13, which includes the PEX5-and PEX14-interacting SH3 domain, is protease-protected in both liposomes and peroxisomes strongly indicating that it faces the lumen of these particles.
To better define the identity of this PK-resistant 28-kDa fragment of PEX13 we subjected it to Edman degradation. This analysis was complicated by the low amount and purity of the reconstituted PEX13 protein (see Fig. 4D ) and yielded the poor-confidence sequence A?-N?-N-X-A?. Nevertheless, it suggested that PK cleaves liposome-reconstituted PEX13 immediately before the 3 rd putative TMD and immediately after the single cysteine residue (Cys220) present in rat PEX13 (see Fig. 5A ).
We know from previous work that treatment of intact rat liver peroxisomes with trypsin yields a slightly larger PEX13 fragment displaying an apparent molecular mass of around 30 kDa [68] . Thus, if the sequence data described above are correct, this 30-kDa fragment should still contain Cys220 whereas the 28-kDa fragment obtained with PK should not. To test this possibility, we subjected rat liver peroxisomes treated with PK or trypsin to a reaction with PEGmaleimide of 5 kDa (PEG-Mal), a cysteine-modifying reagent that increases the apparent molecular mass of proteins by 5-10 kDa per modified residue. The results of this experiment are shown in Fig. 5B . The 28-kDa fragment obtained with PK is not modified with PEGMal whereas the 30-kDa fragment observed in the trypsin digest is. Thus, the region that precedes the third putative TM domain of PEX13 is accessible to both PK and trypsin in intact peroxisomes indicating that this region of the protein faces the cytosol and not the organelle matrix. We must note that this conclusion comes solely from the accessibility of this region of peroxisomal PEX13 to the proteases used in these experiments, and not from the accessibility of Cys220 of PEX13 to PEG-Mal because the peroxisomal membrane is actually permeable to this reagent. Indeed, although a major fraction of the organelles used in these experiments is clearly intact, as assessed by the detergent-sensitive protease-resistant status of full-length SCPx, a peroxisomal matrix protein (Fig. 5B , panel 'anti-SCPx'; band marked with an asterisk in the 60-kDa region), many peroxisomal matrix proteins are shifted to regions of larger molecular masses upon treatment with PEG-Mal. These include SCPx itself, and catalase (band marked with an arrowhead in the Ponceau S-stained membranes). We also note that the permeability of the peroxisomal membrane to PEG-Mal is not an artefact introduced by the lengthy peroxisome isolation procedure (e.g., proteolysis) because the same phenomenon was observed when post-nuclear supernatants from rat organs/tissues were labeled with PEG-Mal and the organelles isolated by a simple centrifugation (unpublished data). Although this finding warrants further investigation, it is probably related to the fact that PEG-Mal is a linear and very narrow molecule and that the peroxisomal membrane contains non-selective channels for many small metabolites [69] . The data above indicate that a domain extending from the third putative TMD of PEX13 to the C terminus of the protein is protease-protected in intact peroxisomes but provide no information regarding the topology of PEX13 residues that precede this region of the protein.
In an attempt to obtain more information on the topology of PEX13, we subjected rat liver peroxisomes to partial proteolysis with trypsin and analyzed the digests by western blot using the anti-PEX13 (342-403) antibody. As shown in Fig. 6 , several PEX13 fragments were detected in this assay, suggesting that several domains of the protein located before TMD3 are exposed into the cytosol. Of note, one of these fragments is just 2-3 kDa shorter than the intact protein, thus suggesting that at least some residues ]-H 6 TEVPEX13 (1-341) were subjected to SDS/PAGE/western blot (Ponceau S-stained membranes are shown), analyzed by autoradiography and probed with the indicated anti-PEX13 antibodies. (D) Proteoliposomes, PK-treated proteoliposomes, and PK alone were analyzed by SDS/PAGE, blotted onto a Sequi-blot PVDF membrane, and stained with Coomassie Brilliant Blue. PK-protected fragment of PEX13 ( , 28 kDa) is indicated. Note that, although these proteoliposomes were sedimented before SDS/PAGE analyses, large amounts of PK and some E. coli contaminants (*, acyl-[-acyl-carrier-protein]-UDP-N-acetylglucosamine O-acyltransferase and Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex; as determined by mass spectrometry analyses (data not shown)) were present in the pelleted vesicles. Numbers to the left indicate the molecular masses of protein standards in kDa.
near the N terminus of PEX13 are located on the cytosolic face of the peroxisomal membrane, in agreement with the available data on the topology of the N terminus of PEX13 [47, 60, 61] (also reviewed in [70] and [57] ). Together, these results suggest that PEX13 has a N out -C in membrane topology, thus exposing its SH3 domain into the organelle matrix.
Discussion
PEX13 and PEX14 are two key components of the DTM involved in several protein-protein interactions. Besides interacting with themselves, yielding homooligomers (a property that might be used to assemble the large pore-like structures at the organelle membrane that the import of already folded proteins demands), PEX13 and PEX14 also interact with each other and with PEX5, the shuttling receptor for peroxisomal matrix proteins. However, although most of the specific domains involved in these interactions are known, our understanding on the actual architecture of the two proteins in the peroxisomal membrane is still incomplete, a fact that has constrained attempts to draw functional implications from the available protein-protein interaction data.
A major question regarding PEX14 concerns its membrane topology. Despite numerous studies performed on PEX14 from different organisms and using several experimental approaches, there is still no consensus regarding the topology of this protein at the peroxisomal membrane. Indeed, models proposing that PEX14 is a peripheral membrane protein exposed into the cytosol [50, 54] or an intrinsic membrane protein with a N out -C out [48, 52] or N in -C out [44, 56, 71] topology have been proposed. Naturally, although PEX14 was recently shown to have intrinsic affinity for lipid bilayers [72] , it could be that PEX14 is bound to the peroxisomal membrane mainly through protein-protein interactions and these might be dynamic or of different strengths in different organisms. However, it is also possible that the different topology models for PEX14 simply reflect limitations of the different experimental approaches that have been used to study this protein (see [70, 73] for a discussion on these issues).
We reasoned that reconstituting PEX14 into liposomes might shed new light on this problem. Our assumption was that a bona fide transmembrane protein subjected to this procedure might acquire a transmembrane topology mimicking the one of the protein in its natural environment and, if so, its membrane architecture could be better characterized. Indeed, from the two PEX14 populations detected in our experiments, one behaved as peroxisomal PEX14 upon protease-protection assays, yielding a PK-protected 20-kDa fragment that comprises approximately amino residues 1-130 of PEX14; the other population yielded a 40-kDa fragment that starts at amino acid residue 100 and probably extends until the C terminus of PEX14 since it is recognized by the anti-PEX14 (327-377) antibody. Thus, these results strongly indicate that PEX14 is an authentic transmembrane protein that possesses a single membrane-spanning domain located between amino acid residue 100 and approximately 130, precisely the region where the only putative TMD detected in all PEX14 proteins is found (see Fig. 1 ).
Although there are no discrepancies in the literature regarding PEX13 membrane topology, it is difficult to conciliate the currently accepted model (i.e., a N out -C out topology with 2 TMDs) with protein-protein interaction data involving PEX13, on one side, and PEX14 and PEX5, on the other. The problem regards the fact that, according to that model, the SH3 domain of PEX13 is exposed into the cytosol although it interacts with a PEX14 domain that, according to our data, faces the organelle matrix. Also, the SH3 domain of PEX13 was shown to interact with the Nterminal half of PEX5, an interaction that according to some authors triggers release of cargo proteins from PEX5 [45, 57, 62] . However, cargo release from PEX5 occurs concomitantly or immediately after insertion of PEX5 into the DTM, away from the cytosol (see Introduction), and thus, how the cytosol-exposed PEX13 SH3 domain might accomplish this task was unclear. The data reported in this work strongly indicate that the SH3 domain of PEX13 actually faces the organelle matrix. Thus, its interaction with PEX14 and its potential role in triggering the release of cargoes from DTM-embedded PEX5 are now easier to understand. Figure 7 integrates the available protein-protein interaction data on PEX5, PEX13 and PEX14 with the membrane topology data described in this work for the two DTM components, namely that PEX14 is a transmembrane protein with N in -C out topology and that PEX13 exposes its N terminus into the cytosol whereas its C-terminal SH3 domain faces the organelle Fig. 6 . N-terminal residues of peroxisomal PEX13 are exposed into the cytosol. Purified peroxisomes were digested with increasing concentrations of trypsin (Try) for 60 min in the absence (À) or presence (+) of TX-100. All samples were precipitated with trichloroacetic acid, subjected to SDS/PAGE and immunoblotted with anti-PEX13 (342-403) antibody. The behavior of sterol carrier protein X (SCPx) was monitored to verify peroxisome integrity. Numbers to the left indicate the molecular masses of protein standards in kDa. matrix. Two features of this model deserve discussion. The first is that both PEX13 and PEX14 possess PEX5-interacting domains on both sides of the peroxisomal membrane. This lends support to the idea that the two peroxins are key components of the transmembrane hydrophilic channel into which PEX5 becomes inserted to release its cargoes into the organelle matrix [5, 74] . The second regards the fact that the cytosolexposed PEX5-binding sites present in both PEX13 and PEX14 are located in regions of these two proteins predicted to be intrinsically disordered. This raises the interesting possibility that cytosolic PEX5-cargo protein complexes are recruited by these flexible PEX13/14 domains to the interior of the DTM, where the stronger interactions that are established between PEX5 and these DTM components lead to the release of the cargo from PEX5.
Materials and methods
Cloning, expression and purification of H 6 TEVPEX14 and H 6 TEVPEX13
The plasmids encoding Rattus norvegicus proteins H 6 PEX14 and H 6 PEX13 -pET28a-PEX14 and PET28a-PEX13 -were synthesized by GenScript with codon optimization for protein expression in E. coli (DNA sequences available from the authors upon request). The plasmids were then digested with NdeI, dephosphorylated with calf intestine phosphatase (New England BioLabs, Ipswich, MA, USA), and ligated to an adapter encoding the recognition sequence of the TEV protease, yielding pET28a-TEVPEX14 and pET28a-TEVPEX13. The adaptor was obtained by annealing the 5 0 -phosphorylated oligonucleotides 5 0 -TATGGAGAACCTTTATTTCCAGGGCCA-3 0 and 5 0 -TATGGCCCTGGAAATAAAGGTTCTCCA-3 0 using standard procedures [75] . The plasmids pET28a-TEVPEX14 and pET28a-TEV-PEX13 were transformed into E. coli BL21 (DE3) competent cells for expression. Cells were grown in LB media (NZYTech, Lisboa, Portugal) at 37°C and the expression was induced by adding 1 mM IPTG.
For purification of H 6 TEVPEX14, cells were resuspended in lysis buffer containing 50 mM Tris.HCl pH 8.0, 150 mM NaCl, 1 mM EDTA pH 8.0, 1 mM DTT, 1 : 500 (v/v) protease inhibitor cocktail (Sigma-Aldrich, Saint Louis, MO, USA; #P8340), 0.6 mM phenylmethylsulfonyl fluoride, 0.2 mgÁmL À1 lysozyme and 1.2% (w/v) DDM (Anatrace; #D310S) and lysed by sonication on ice. The lysate was clarified by centrifugation (15 min at 13 000 rpm, 4°C in a table top centrifuge) and the supernatant was incubated overnight at 4°C with HIS-Select Nickel Affinity Gel beads (Sigma-Aldrich) in the presence of 2 mM imidazole. The beads were washed three times with 150 mM NaCl, 0.05% (w/v) DDM, 0. 
Reconstitution of proteins into liposomes
The lipids L-a-phosphatidylcholine (PC; Sigma-Aldrich), La-phosphatidylethanolamine (PE; Sigma-Aldrich) and 1,2-dioleoyl-sn-glycero-3-phospho-L-serine, (PS; Avanti, Alabaster, AL, USA) were purchased as chloroform solutions. Lipids were mixed in the proportion (w/w) 57% PC: 38% PE: 5% PS, and the chloroform was evaporated under a stream of N 2 . Residual chloroform was removed in a freeze dryer for 2 h. [64] [65] [66] 77] . In brief, DDM was slowly removed by two successive incubations of 1 h each (50 mg Bio-Beads per milligram of DDM; room temperature), followed by a third overnight incubation (100 mg Bio-Beads per milligram of DDM; 4°C). The beads were sedimented by gravity and the proteoliposome suspension was recovered by pipetting the supernatant avoiding the Bio-Beads.
Protease-protection assays
Protease-protection assays were performed as described previously [78] . Briefly, proteoliposomes and highly pure peroxisomes were treated with PK (200-400 lgÁmL
À1
; final concentration) or trypsin (5-400 lgÁmL
; final concentration) for 1.5 h on ice, unless stated otherwise. The proteases were inactivated with phenylmethylsulfonyl fluoride (500 lgÁmL
; final concentration) or with a protease inhibitors cocktail [1% (v/v)] for 2 min on ice. In some samples, proteoliposomes and peroxisomes were incubated with 0.5% (w/v) TX-100 for 5 min on ice, before adding the protease. Samples to be analyzed by liquid chromatography-mass spectrometry (LC-MS/MS) or by Edman degradation were additionally centrifuged 2 h at 100 000 g (4°C; Beckman Optima L80-XP, rotor 70.1 Ti), in order to decrease the amount of PK in the proteoliposomes. All samples were subjected to 10% (w/v) trichloroacetic acid precipitation. After SDS/PAGE, gels were stained with Coomassie Brilliant Blue (samples for LC-MS/MS) or blotted onto a PVDF membrane (samples for Edman degradation; also stained with Coomassie Brilliant Blue) or onto a nitrocellulose membrane (samples for immunodetection; stained with Ponceau S).
PEGylation assays after digestion with proteases
PEGylation assays were performed with purified rat liver peroxisomes in import buffer (20 mM MOPS, 0.25 M sucrose, 50 mM KCl, 5 mM MgCl 2 , 96 lM methionine, 2 lgÁmL À1 trans-Epoxysuccinyl-L-leucylamido(4-guanidino)
butane; pH adjusted to 7.4 at 4°C with KOH). The organelles were pretreated first with 0.5 mM TCEP (10 min on ice) and then with either PK or trypsin (Sigma-Aldrich; 30 min on ice). In some samples, peroxisomes received 0.5% (w/v) TX-100 before adding the protease. The proteases were inactivated with 1% (v/v) of protease inhibitor cocktail. Methoxy-PEG-maleimide (PEG-Mal) 5000 Da (4 mM, final concentration; Sigma-Aldrich; #63187) was added to peroxisomes and the suspensions were incubated for 30 min on ice. The reaction was stopped with 100 mM DTT for 5 min on ice and phenylmethylsulfonyl fluoride was added to 500 lgÁmL
À1
. After 2 min on ice, the organelle suspensions were diluted to 1 mL with import buffer and centrifuged at 11 300 g for 20 min at 4°C to pellet the organelles. All samples were subjected to precipitation with 10% (w/v) trichloroacetic acid and analyzed by SDS/ PAGE/western blotting.
Antibodies
The following antibodies were used: rabbit antibody against full-length human PEX14 protein [14] , rabbit antibody against amino acid residues 327-377 of human PEX14 protein (Bethyl laboratories. Inc; #A303-086A), rabbit antibody directed to amino acid residues 342-403 of human PEX13 protein (Ray Biotech, Norcross, GA, USA; #107-10608), rabbit antibody produced against a recombinant histidinetagged human PEX13 (219-403) by AMS Biotechnology [74] , mouse antibody produced against Tetra-His (Qiagen, Venlo, the Netherlands; #34670), and rabbit anti-sterol carrier protein X antibody (SCPx; 19182-1-AP, ProteinTech TM ). Primary antibodies were detected using goat alkaline phosphatase-conjugated anti-rabbit or anti-mouse antibodies (#A9919 and #A2429, respectively, Sigma-Aldrich).
LC-MS/MS analysis
Protein bands were excised from SDS/PAGE, reduced with DTT, and alkylated with IAA as previously described [79] , and subsequently digested with trypsin or chymotrypsin. The resulting peptides were desalted and concentrated using reverse phase C18 tips (ZipTips, Millipore) following the manufacturer's instructions, eluted in 60% acetonitrile (ACN)/0.1% trifluoroacetic acid (TFA), and dried (SpeedVac, Thermo Fisher Scientific, Waltham, MA, USA).
The re-solubilized peptides were analyzed by liquid chromatography (LC) coupled to an Orbitrap Q-Exactive mass spectrometer (Thermo Scientific) using a nanospray ionization source (Easy-Spray, Thermo Fisher Scientific). Reverse phase peptide separation was performed with an Ultimate 3000 system (Thermo Scientific) fitted with a trapping cartridge (Acclaim PepMap C18 100 A, 5 mm 9 300 lm i.d., 160454, Thermo Scientific) in a mobile phase of 2% ACN, 0.1% formic acid (FA) at 10 lLÁmin The raw data were processed using PROTEOME DISCOVERER 2.2.0.388 software (Thermo Scientific) and searched against the UniProt database for the taxonomic selection Rattus norvegicus (November 2017 release). Sequest HT search engine was used to identify tryptic and chymotryptic peptides. The ion mass tolerance was 10 ppm for precursor ions and 0.02 Da for fragment ions. Maximum allowed missing cleavage sites was set 2. Cysteine carbamidomethylation and methionine oxidation were defined as constant and variable modifications, respectively.
Miscellaneous
For the preparation of highly pure peroxisomes, male Wistar Han rats, with 6-8 weeks of age, were fasted overnight and euthanized following the guidelines/protocols approved by the IBMC Animal Ethics Committee (CEA -Comissão de Etica Animal). All experimental protocols were approved by the Portuguese General Veterinarian Board (DGAV -Direcc ßão Geral de Alimentac ßão e Veterin aria). After liver extraction, peroxisomes were purified by differential centrifugation and Nycodenz gradient purification, as previously described [80, 81] .
Edman degradation of protein bands excised from a SequiBlot PVDF membrane (Bio-Rad) was performed by AltaBioscience (University of Birmingham, United Kingdom).
The cDNA encoding the first 341 amino acid residues of PEX13 was obtained by PCR amplification of pET28a-TEVPEX13 using the primers 
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